[Form 4] Precigen, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Precigen Chief Commercial Officer Phil Tennant received a significant equity compensation award on June 26, 2025, consisting of 125,000 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of Precigen common stock upon vesting.

The RSUs follow a specific vesting schedule: 50% will vest on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years. The grant was awarded at $0 exercise price, as is typical for RSU compensation.

This Form 4 filing, submitted by Tennant's attorney-in-fact Donald P. Lehr, reflects standard executive compensation practices and aligns the executive's interests with long-term shareholder value through the extended vesting period.

Positive

• Chief Commercial Officer received 125,000 RSUs with long-term vesting schedule (4 years), promoting retention and alignment with shareholder interests

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tennant Phil

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/26/2025		A		125,000		(2)	(2)	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vest 50% on May 23, 2026 and in equal monthly installments for three years thereafter.

	/s/ Phil Tennant, by Donald P. Lehr, as attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Restricted Stock Units (RSUs) did PGEN's Chief Commercial Officer receive on June 26, 2025?

PGEN's Chief Commercial Officer Phil Tennant received 125,000 Restricted Stock Units (RSUs) on June 26, 2025. Each RSU represents a contingent right to receive one share of Precigen common stock.

What is the vesting schedule for PGEN CCO's new RSU grant?

The RSUs granted to PGEN's CCO will vest 50% on May 23, 2026, with the remaining 50% vesting in equal monthly installments over the following three years.

Who is Phil Tennant at PGEN and what was his insider transaction?

Phil Tennant is the Chief Commercial Officer of Precigen (PGEN). He was granted 125,000 RSUs on June 26, 2025, as reported in this Form 4 filing. The RSUs were acquired at a price of $0.

What is PGEN insider Phil Tennant's business address?

Phil Tennant's business address as listed on the Form 4 is 20374 Seneca Meadows Parkway, Germantown, MD 20876.